Condition: Hepatocellular Carcinoma · Sponsor: Febico Biomedical Corp.
The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization. The main question it aims to answer is: Changes in the level of liver function parameters, including AST, ALT, or total bilirubin, from baseline to Visit 3, Visit 4, Visit 5, and Visit 6 There is a comparison group: Researchers will compare arm 1 placebo to see if FB-1603 is work to treat the liver function. Participants will 1. Take drug FB-1603 990mg/day, FB-1603 1980mg/day or a placebo every day for 10 weeks. 2. Visit the clinic on day 4, 7, 10, 14, 28, 56 and 84 (follow-up)
This description comes directly from the study's public registry record.
Tsung-Yen Ho, Master · 886-2-2627-5585 · rdrad001@gmail.com
Jyun-Yuan Huang, Doctor · 886-2-2627-5585 · jyhuang@febico.com.tw
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06478719